Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 568 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 568 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $14,870.24. Following the sale, the chief operating officer now directly owns 236,286 shares in the company, valued at $6,185,967.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Thursday, August 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.75, for a total transaction of $133,750.00.
• On Monday, July 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $23.40, for a total transaction of $117,000.00.

Akero Therapeutics Trading Up 6.4 %

Shares of Akero Therapeutics stock opened at $27.34 on Friday. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -8.54 and a beta of -0.26. The company has a fifty day simple moving average of $25.99 and a 200-day simple moving average of $23.99. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12-month low of $11.25 and a 12-month high of $53.77.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09. On average, equities analysts forecast that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on AKRO shares. Wolfe Research started coverage on shares of Akero Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.13.

Institutional Trading of Akero Therapeutics

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in shares of Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after acquiring an additional 1,183 shares during the period. Quarry LP lifted its stake in shares of Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after acquiring an additional 500 shares during the period. Quest Partners LLC purchased a new position in shares of Akero Therapeutics in the 4th quarter valued at about $75,000. Headlands Technologies LLC increased its holdings in shares of Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after purchasing an additional 3,024 shares in the last quarter. Finally, Global Retirement Partners LLC increased its holdings in shares of Akero Therapeutics by 54.5% in the 1st quarter. Global Retirement Partners LLC now owns 5,747 shares of the company’s stock valued at $145,000 after purchasing an additional 2,028 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.